AQR Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

AQR Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,166	Closed	-$397K	–	2320
2023 Q1	$397K	Buy	17,166 +959	+6%	+$22.9K	﹤0.01%	1849
2022 Q4	$425K	Buy	16,207 +2,294	+16%	+$50.8K	﹤0.01%	1866
2022 Q3	$274K	Buy	+13,913	New	+$279K	﹤0.01%	1971
2019 Q4	–	Sell	-247,940	Closed	-$1.31M	–	2198
2019 Q3	$1.31M	Buy	247,940 +107,618	+77%	+$714K	﹤0.01%	1442
2019 Q2	$1.08M	Buy	140,322 +60,515	+76%	+$922K	﹤0.01%	1467
2019 Q1	$1.59M	Buy	+79,807	New	+$1.39M	﹤0.01%	1407
2016 Q4	–	Sell	-3,784	Closed	-$235K	–	2295
2016 Q3	$235K	Sell	3,784 -10,729	-74%	-$758K	﹤0.01%	2129
2016 Q2	$821K	Buy	+14,513	New	+$882K	﹤0.01%	1687

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Capital Management's KDNY Position: Q2 2023 in Review

AQR Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 17,166 shares — an estimated $397K sold.

AQR Capital Management first reported a position in KDNY in Q2 2016 and held it in 8 quarters. The position peaked at $1.59M in Q1 2019. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

AQR Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
AQR Capital Management sold 17,166 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $397K.
AQR Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2016 and held it in 8 quarters.
AQR Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $1.59M in Q1 2019.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on AQR Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.